159 related articles for article (PubMed ID: 23435474)
1. The opportunity cost of androgen suppression in locally advanced prostate cancer.
Gray PJ; Efstathiou JA; Shipley WU
Asian J Androl; 2013 May; 15(3):356-7. PubMed ID: 23435474
[No Abstract] [Full Text] [Related]
2. Harms versus benefits with duration of androgen suppression.
Nguyen PL
Lancet Oncol; 2012 Dec; 13(12):1182-3. PubMed ID: 23151430
[No Abstract] [Full Text] [Related]
3. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
[TBL] [Abstract][Full Text] [Related]
4. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer: androgen suppression duration and zoledronic acid: under the RADAR.
Hutchinson L
Nat Rev Urol; 2014 Nov; 11(11):599. PubMed ID: 25201618
[No Abstract] [Full Text] [Related]
6. Prostate cancer: Androgen suppression duration and zoledronic acid: under the RADAR.
Hutchinson L
Nat Rev Clin Oncol; 2014 Oct; 11(10):559. PubMed ID: 25200412
[No Abstract] [Full Text] [Related]
7. Management of advanced prostate cancer.
von Eyben F; Kiljunen T; Kangasmaki A; Kairemo K; von Eyben R; Joensuu T
Ann Oncol; 2015 Nov; 26(11):2354. PubMed ID: 26216387
[No Abstract] [Full Text] [Related]
8. Role of bisphosphonates in non-metastatic prostate cancer.
Saad F
Lancet Oncol; 2014 Sep; 15(10):1041-2. PubMed ID: 25130993
[No Abstract] [Full Text] [Related]
9. Reply to the letter to the editor 'management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015' by Gillessen et al.
Gillessen S; Fanti S; Omlin A;
Ann Oncol; 2015 Nov; 26(11):2354-5. PubMed ID: 26347101
[No Abstract] [Full Text] [Related]
10. [Treatment of prostate cancer].
Romics I
Orv Hetil; 2010 Apr; 151(14):580-3. PubMed ID: 20332076
[No Abstract] [Full Text] [Related]
11. Interstitial pneumonitis associated with neoadjuvant leuprolide and nilutamide for prostate cancer.
Wieder JA; Soloway MS
J Urol; 1998 Jun; 159(6):2099. PubMed ID: 9598539
[No Abstract] [Full Text] [Related]
12. Editorial comment.
Tan WW
Urology; 2010 May; 75(5):1143. PubMed ID: 20451736
[No Abstract] [Full Text] [Related]
13. RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients.
Kachnic LA; Pugh SL; Tai P; Smith M; Gore E; Shah AB; Martin AG; Kim HE; Nabid A; Lawton CA
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):382-6. PubMed ID: 24080992
[TBL] [Abstract][Full Text] [Related]
14. Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer.
Denham JW; Nowitz M; Joseph D; Duchesne G; Spry NA; Lamb DS; Matthews J; Turner S; Atkinson C; Tai KH; Gogna NK; Kenny L; Diamond T; Smart R; Rowan D; Moscato P; Vimieiro R; Woodfield R; Lynch K; Delahunt B; Murray J; D'Este C; McElduff P; Steigler A; Kautto A; Ball J
BJU Int; 2014 Sep; 114(3):344-53. PubMed ID: 24512527
[TBL] [Abstract][Full Text] [Related]
15. Re: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Pitts WR
J Urol; 2003 Dec; 170(6 Pt 1):2392-3; author reply 2393-4. PubMed ID: 14634434
[No Abstract] [Full Text] [Related]
16. Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients.
Cai T; Bartoletti R
J Clin Oncol; 2007 Aug; 25(22):3385; author reply 3385-6. PubMed ID: 17664492
[No Abstract] [Full Text] [Related]
17. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.
Lang JM; Wallace M; Becker JT; Eickhoff JC; Buehring B; Binkley N; Staab MJ; Wilding G; Liu G; Malkovsky M; McNeel DG
Clin Genitourin Cancer; 2013 Dec; 11(4):407-15. PubMed ID: 23835291
[TBL] [Abstract][Full Text] [Related]
19. Annual zoledronic acid: is less more?
Higano CS
J Clin Oncol; 2007 Mar; 25(9):1026. PubMed ID: 17369565
[No Abstract] [Full Text] [Related]
20. [Evolution of endocrine therapy for prostate cancer].
Igawa T; Saito Y
Nihon Rinsho; 2000 Jul; 58 Suppl():176-81. PubMed ID: 11022709
[No Abstract] [Full Text] [Related]
[Next] [New Search]
